Before you go!

Sign up for the FREE weekly email newsletter from the publishers of American Nurse Today. You’ll get breaking news features, exclusive investigative stories, and more — delivered to your inbox.

Sign up today!

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

FDA recommends close cardiovascular monitoring after first dose of Gilenya

One May 14, the U.S. Food and Drug Administration (FDA) recommended that patients starting on the multiple sclerosis drug Gilenya (fingolimod) be monitored for bradycardia for at least 6 hours after the first dose. The recommendation came after a review of additional clinical trial and postmarketing reports for Gilenya, including reports of patients dying of cardiovascular events or unknown causes. Although the FDA could not definitively conclude that Gilenya was related to any of the deaths, it “remains concerned about the cardiovascular effects of Gilenya after the first dose.” Although the maximum heart rate lowering effect of Gilenya usually occurs within 6 hours of the first dose, the maximum effect may occur as late as 20 hours after the first dose. Read more.

Leave a Reply

You have to agree to the comment policy.


Test Your Nursing Knowledge

Answer this interactive quiz to be entered to win a gift card.

  • This field is for validation purposes and should be left unchanged.

Insights Blog

Today’s News in Nursing